Explore All 159 IPO Financial Services Deals - Search the Database Free
Investment Summary |
|
|---|---|
| Date | June 13, 2013 |
| Target | Silvercrest Asset Management Group |
| Sector | Financial Services |
| Sellers(s) | Vulcan Capital |
| Deal Type | IPO |
FILTER BY
| Category | Family Office |
|---|---|
| Founded | 1986 |
| Size | Mega |
| Type | Sector Agnostic |
Vulcan Capital is the private investment group of Vulcan Inc., the organization founded by Paul G. Allen to manage his personal and professional endeavors. Vulcan Capital looks to invest at all company stages and will consider opportunities across an array of industries. Sectors of interest include business services, consumer products, distribution and logistics, energy and natural resources, financial services and insurance, healthcare, manufacturing, media, technology, and telecom. The Firm's target investment size is $10 to $100 million. In addition to direct investing, Vulcan Capital also makes fund investments as well as invests in public securities. Vulcan Inc. was formed in 1986 and has offices in Seattle, Washington and Palo Alto, California.
| Deal Context for Seller | # |
|---|---|
| Overall | 11 of 30 |
| Sector: Financial Services | 1 of 3 |
| Type: IPO | 3 of 9 |
| State: New York | 2 of 4 |
| Country: United States | 10 of 28 |
| Year: 2013 | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-01-15 |
Masthead Industries
Orange Park, Florida, United States Masthead Industries is engaged in sale and distribution of industrial, hydraulic hoses and fittings, hydraulic hose assembly systems, and mobile repair service carrying over 46,000 SKUs. Masthead primarily serves the mining, construction and manufacturing industries through over thirty locations across the United States, Canada and Mexico. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-06-20 |
PTC Therapeutics
South Plainfield, New Jersey, United States PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. PTC Therapeutics was founded in 1998 and is based in South Plainfield, New Jersey. |
Sell | - |